Steven I. Sherman

RET-driven osteoprotegerin expression links medullary thyroid cancer to osteoblastic bone metastases

Rozita Bagheri-Yarmand, Gabriel M. Pagnotti, Joseph L. Kidd, David Ávila Ramírez et autres

Development of bone metastases increases mortality in patients with medullary thyroid cancer (MTC), with ∼50% survival at 5 years after diagnosis, but the underlying mechanisms of action are unknown. We show that patient-derived MTC cells ( RET C634W mutant TT and RET …

us (code pays fourni par la source)

Patient-Reported Symptom Burden Among Thyroid Cancer Survivors: Retrospective Cohort Study

Jason B. Liu, Thomas Szabo Yamashita, Johnny L. Rollins, Soo-Hyun Lee-Kim et autres

PURPOSE: Survivorship care models that extend beyond recurrence surveillance to ones that also address treatment-related symptoms are needed. Using data obtained in routine clinical care, we aimed to examine patient-reported symptom burden among adult thyroid cancer survivors. METHODS: Between September 2019 and …

us (code pays fourni par la source)

Revised Thyroid Differentiation Score for Risk Stratification in Papillary Thyroid Carcinoma

Vicente Rodrigues Marczyk, Chia-Chin Wu, Sarah Hamidi, Sophie H. Li et autres

PURPOSE Loss of thyroid differentiation underlies the aggressive behavior of a subset of papillary thyroid carcinomas (PTCs). The Thyroid Differentiation Score (TDS), introduced by The Cancer Genome Atlas (TCGA), quantifies tumor differentiation but has limited reproducibility and clinical applicability. We developed and …

us (code pays fourni par la source)

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status

Marcia S. Brose, B. Keam, Jolanta Krajewska, Ana Oliveira Hoff et autres

Background Cabozantinib is approved for previously treated radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) based on improved progression-free survival (PFS) versus placebo in the COSMIC-311 study. The BRAF V600E mutation is common in DTC and is associated with poor prognosis. This planned exploratory analysis …

us, kr, hu, br, co, cl, mx, tw, au, th (code pays fourni par la source)

Acquired Driver Fusions as a Mechanism of Resistance to Selective RET Inhibitors in Advanced Medullary Thyroid Carcinoma

Sarah Azzahra Hamidi, Vivek Subbiah, Maria E. Cabanillas, Steven I. Sherman et autres

us (code pays fourni par la source)

Increasing Access and Quality Care for Immune Checkpoint Inhibitor–Related Thyroid Dysfunction

Anne Brinkman, Amori Y. Salami-Henry, Lori Aaron-Brija, Faheemah M. Hannah et autres

PURPOSE The use of immunotherapy for cancer treatment is becoming increasingly prevalent, resulting in a growing number of patients experiencing immune-related adverse events (irAEs). Given the frequency of immunotherapy-related thyroid dysfunction (irTD), there is a growing demand for endocrine consultations, which has …

us (code pays fourni par la source)

International Consensus on the Requirements for Definitions of Complete Remission and Recurrence of Differentiated Thyroid Cancer: a Delphi Study (ICON-DTC)

Daniël J. van de Berg, Hanneke M. van Santen, Sarah Clement, Menno R. Vriens et autres

OBJECTIVE: Recurrence is a key outcome measure of treatment for differentiated thyroid carcinoma (DTC). In international guidelines and current literature, a consistent definition is lacking, which hinders comparison of treatment-related oncological outcomes. Therefore, the aim of this study was to reach international …

nl, de, se, ro, it, hu, pl, Ghana (code pays fourni par la source)

MON-336 Diagnostic Utility of I 123 Hybrid SPECT/CT in the Characterization of Retropharyngeal Masses

Maryam Khan, Steven I. Sherman, Jill E. Langer, Laurie A. Loevner et autres

Abstract Disclosure: M.I. Khan: None. S.I. Sherman: None. J.E. Langer: None. L.A. Loevner: None. C. Schmalbach: None. N. Vijayvargia: None. D. Weinberg: None. S. Rubin: None. J.W. Lazor: None. R. Viterbo: None. A. Kutikov: None. R. Satriale: None. K. Chernukha: None. N. …

us (code pays fourni par la source)

Activating RET Mutations Promotes Osteoblastic Bone Metastases in Medullary Thyroid Cancer

Rozita Bagheri‐Yarmand, Gabriel M. Pagnotti, Joseph L. Kidd, David Ramírez et autres

Summary Development of bone metastases increases mortality in patients with medullary thyroid cancer (MTC), with ∼50% survival at 5 years after diagnosis, but the underlying mechanisms are unknown. We show that patient-derived MTC cells ( RET C634W mutant TT cells and RET …

us (code pays fourni par la source)

Erratum: NTRK Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy

Vicente Rodrigues Marczyk, Sasan Fazeli, Ramona Dadu, Naifa L. Busaidy et autres

Characterization of Advanced RAS -driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues

Sarah Hamidi, Anastasios Maniakas, Neal S. Akhave, Victoria Banuchi et autres

CONTEXT: With novel RAS-targeted therapies emerging, better understanding of RAS-driven differentiated (DTC) and anaplastic (ATC) thyroid cancers is warranted. OBJECTIVE: Characterize the genotypic and phenotypic landscape of RAS-driven DTC and ATC and review current and future therapeutic avenues. DESIGN: Retrospective chart review …

us (code pays fourni par la source)

NTRK Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy

Vicente Rodrigues Marczyk, Sasan Fazeli, Ramona Dadu, Naifa L. Busaidy et autres

PURPOSE Neurotrophic tropomyosin receptor kinase ( NTRK ) fusions may act as an oncogenic driver in thyroid carcinomas. Given their low frequency, clinical, pathological, and molecular data on these patients and their responses to targeted therapies are limited. METHODS This is an …

us (code pays fourni par la source)